These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31695341)

  • 1. Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET).
    Ström T; Kozlovacki G; Myrenfors P; Almquist M
    Patient Prefer Adherence; 2019; 13():1799-1807. PubMed ID: 31695341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRESTO 2: An International Survey to Evaluate Patients' Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly.
    O'Toole D; Kunz PL; Webb SM; Goldstein G; Khawaja S; McDonnell M; Boiziau S; Gueguen D; Houchard A; Ribeiro-Oliveira A; Prebtani A
    Adv Ther; 2023 Feb; 40(2):671-690. PubMed ID: 36502449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An international simulated-use study to assess nurses' preferences between two lanreotide syringes for patients with neuroendocrine tumours or acromegaly (PRESTO 3).
    Ferone D; Martin W; Williams J; Houchard A; Pommie C; Ribeiro-Oliveira A; Grossman AB
    J Endocrinol Invest; 2024 Feb; 47(2):421-432. PubMed ID: 37550552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of Care Among Real-World Patients with Metastatic Neuroendocrine Tumors.
    Klink AJ; Feinberg B; Yu HT; Ray D; Pulgar S; Phan A; Vinik A
    Oncologist; 2019 Oct; 24(10):1331-1339. PubMed ID: 31015313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A qualitative study to understand the experience of somatostatin analog treatments from the perspective of patients with neuroendocrine tumors.
    Seo C; Horodniceanu E; Shah R; Goldstein G; Ray D; Bennett B; Phan A; McCarrier K
    Support Care Cancer; 2022 Jul; 30(7):6307-6316. PubMed ID: 35476113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Study of Lanreotide Autogel in Routine Practice in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Hong Kong and Taiwan.
    Chen JS; Bai LY; Cheng HH; Chan SL; Zou JY; Shi X; Houchard A; Truong-Thanh XM; Chen MH
    Oncol Ther; 2024 Aug; ():. PubMed ID: 39215958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis.
    Ryan P; McBride A; Ray D; Pulgar S; Ramirez RA; Elquza E; Favaro JP; Dranitsaris G
    J Oncol Pharm Pract; 2019 Sep; 25(6):1425-1433. PubMed ID: 30924737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Patterns of Long-Acting Somatostatin Analogs for Neuroendocrine Tumors.
    Clarke CN; Cockrum P; Beveridge TJR; Jerry M; McMorrow D; Tran AT; Phan AT
    J Health Econ Outcomes Res; 2023; 10(2):121-131. PubMed ID: 38093906
    [No Abstract]   [Full Text] [Related]  

  • 9. Antiproliferative Effect of Above-Label Doses of Somatostatin Analogs for the Management of Gastroenteropancreatic Neuroendocrine Tumors.
    Diamantopoulos LN; Laskaratos FM; Kalligeros M; Shah R; Navalkissoor S; Gnanasegaran G; Banks J; Smith J; Jacobs B; Galanopoulos M; Mandair D; Caplin M; Toumpanakis C
    Neuroendocrinology; 2021; 111(7):650-659. PubMed ID: 32541155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO).
    Adelman D; Truong Thanh XM; Feuilly M; Houchard A; Cella D
    Adv Ther; 2020 Apr; 37(4):1608-1619. PubMed ID: 32157626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-Administration of Long-Acting Somatostatin Analogues in NET Patients-Does It Affect the Clinical Outcome?
    Sowa-Staszczak A; Opalińska M; Kurzyńska A; Morawiec-Sławek K; Gilis-Januszewska A; Palen-Tytko J; Olearska H; Hubalewska-Dydejczyk A
    Medicina (Kaunas); 2021 Nov; 57(12):. PubMed ID: 34946232
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors.
    Saif MW; Fu J; Smith MH; Weinstein B; Relias V; Daly KP
    J Pancreat Cancer; 2018; 4(1):64-71. PubMed ID: 30788459
    [No Abstract]   [Full Text] [Related]  

  • 13. External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study.
    Jimenez-Fonseca P; Carmona-Bayonas A; Lamarca A; Barriuso J; Castaño A; Benavent M; Alonso V; Riesco MDC; Alonso-Gordoa T; Custodio A; Sanchez Canovas M; Hernando J; López C; La Casta A; Fernandez Montes A; Marazuela M; Crespo G; Diaz JA; Feliciangeli E; Gallego J; Llanos M; Segura A; Vilardell F; Percovich JC; Grande E; Capdevila J; Valle J; Garcia-Carbonero R
    Neuroendocrinology; 2022; 112(1):88-100. PubMed ID: 33508849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
    Vinik AI; Wolin EM; Liyanage N; Gomez-Panzani E; Fisher GA;
    Endocr Pract; 2016 Sep; 22(9):1068-80. PubMed ID: 27214300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study.
    Adelman DT; Burgess A; Davies PR
    Med Devices (Auckl); 2012; 5():103-9. PubMed ID: 23293542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term experience with octreotide and lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.
    Kiesewetter B; Pflüger FF; Melhorn P; Mazal P; Raderer M
    Clin Transl Oncol; 2024 Sep; ():. PubMed ID: 39316250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
    Fisher GA; Wolin EM; Liyanage N; Lowenthal SP; Mirakhur B; Pommier RF; Shaheen M; Vinik AI;
    Endocr Pract; 2018 Mar; 24(3):243-255. PubMed ID: 29547049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors.
    Ayyagari R; Neary M; Li S; Rokito A; Yang H; Xie J; Benson AB
    Am Health Drug Benefits; 2017 Nov; 10(8):408-415. PubMed ID: 29263774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
    Chanson P; Boerlin V; Ajzenberg C; Bachelot Y; Benito P; Bringer J; Caron P; Charbonnel B; Cortet C; Delemer B; Escobar-Jiménez F; Foubert L; Gaztambide S; Jockenhoevel F; Kuhn JM; Leclere J; Lorcy Y; Perlemuter L; Prestele H; Roger P; Rohmer V; Santen R; Sassolas G; Scherbaum WA; Schopohl J; Torres E; Varela C; Villamil F; Webb SM
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):577-86. PubMed ID: 11106918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
    Öberg K; Lamberts SW
    Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.